These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26095933)

  • 41. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
    O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
    Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Institutional Experience on Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy.
    Veselka J; Faber L; Jensen MK; Cooper R; Januska J; Krejci J; Bartel T; Dabrowski M; Hansen PR; Almaas VM; Seggewiss H; Horstkotte D; Adlova R; Bundgaard H; Ten Berg J; Liebregts M
    Can J Cardiol; 2018 Jan; 34(1):16-22. PubMed ID: 29275877
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.
    Li CH; Lin YJ; Huang JL; Wu TJ; Cheng CC; Lin WS; Tuan TC; Chang SL; Lo LW; Hu YF; Chao TF; Chung FP; Tsai CF; Tsao HM; Chen SA
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):750-6. PubMed ID: 22353378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry.
    Veselka J; Jensen MK; Liebregts M; Januska J; Krejci J; Bartel T; Dabrowski M; Hansen PR; Almaas VM; Seggewiss H; Horstkotte D; Tomasov P; Adlova R; Bundgaard H; Steggerda R; Ten Berg J; Faber L
    Eur Heart J; 2016 May; 37(19):1517-23. PubMed ID: 26746632
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can QRS scoring predict left ventricular scar and clinical outcomes?
    Rosengarten JA; Scott PA; Chiu OK; Shambrook JS; Curzen NP; Morgan JM
    Europace; 2013 Jul; 15(7):1034-41. PubMed ID: 23493411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy.
    O'Mahony C; Lambiase PD; Quarta G; Cardona M; Calcagnino M; Tsovolas K; Al-Shaikh S; Rahman SM; Arnous S; Jones S; McKenna W; Elliott P
    Heart; 2012 Jan; 98(2):116-25. PubMed ID: 21757459
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness and safety beyond 10 years of percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy.
    de la Torre Hernandez JM; Masotti Centol M; Lerena Saenz P; Sánchez Recalde Á; Gimeno de Carlos F; Piñón Esteban P; Fernandez Rodriguez D; Sitges Carreño M; Sabate Tenas M; Zueco Gil J
    Rev Esp Cardiol (Engl Ed); 2014 May; 67(5):353-8. PubMed ID: 24774727
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age.
    Maron BJ; Rowin EJ; Casey SA; Haas TS; Chan RH; Udelson JE; Garberich RF; Lesser JR; Appelbaum E; Manning WJ; Maron MS
    Circulation; 2013 Feb; 127(5):585-93. PubMed ID: 23275385
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.
    Prinz C; Schwarz M; Ilic I; Laser KT; Lehmann R; Prinz EM; Bitter T; Vogt J; van Buuren F; Bogunovic N; Horstkotte D; Faber L
    Can J Cardiol; 2013 Mar; 29(3):358-63. PubMed ID: 22749647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
    Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
    Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation.
    Gatzoulis KA; Vouliotis AI; Tsiachris D; Salourou M; Archontakis S; Dilaveris P; Gialernios T; Arsenos P; Karystinos G; Sideris S; Kallikazaros I; Stefanadis C
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):504-12. PubMed ID: 23588627
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD?
    Wichter T; Paul TM; Eckardt L; Gerdes P; Kirchhof P; Böcker D; Breithardt G
    Herz; 2005 Mar; 30(2):91-101. PubMed ID: 15875097
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival and sudden cardiac death after septal ablation for hypertrophic obstructive cardiomyopathy.
    Jensen MK; Havndrup O; Hassager C; Helqvist S; Kelbæk H; Jørgensen E; Køber L; Bundgaard H
    Scand Cardiovasc J; 2011 Jun; 45(3):153-60. PubMed ID: 21604920
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.
    Maron BJ; Rowin EJ; Casey SA; Lesser JR; Garberich RF; McGriff DM; Maron MS
    Circulation; 2016 Jan; 133(1):62-73. PubMed ID: 26518766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Septal myectomy after failed alcohol ablation: Does previous percutaneous intervention compromise outcomes of myectomy?
    Quintana E; Sabate-Rotes A; Maleszewski JJ; Ommen SR; Nishimura RA; Dearani JA; Schaff HV
    J Thorac Cardiovasc Surg; 2015 Jul; 150(1):159-67.e1. PubMed ID: 25940414
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial.
    Barsheshet A; Goldenberg I; Moss AJ; Huang DT; Zareba W; McNitt S; Klein HU; Guetta V
    J Cardiovasc Electrophysiol; 2011 Nov; 22(11):1237-42. PubMed ID: 21615813
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy.
    Woo A; Monakier D; Harris L; Hill A; Shah P; Wigle ED; Rakowski H; Rozenblyum E; Cameron DA
    Heart; 2007 Sep; 93(9):1044-5. PubMed ID: 17699173
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Left ventricular scar burden specifies the potential for ventricular arrhythmogenesis: an LGE-CMR study.
    Scott PA; Rosengarten JA; Murday DC; Peebles CR; Harden SP; Curzen NP; Morgan JM
    J Cardiovasc Electrophysiol; 2013 Apr; 24(4):430-6. PubMed ID: 23210601
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy.
    Francia P; Santini D; Musumeci B; Semprini L; Adduci C; Pagannone E; Proietti G; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2014 Nov; 25(11):1180-7. PubMed ID: 25066044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.